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Sporadic inclusion body myositis (IBM) is a muscle
disease with two separate pathogenic components,
degeneration and inflammation. Typically, nonne-
crotic myofibers are focally surrounded and invaded
by CD8
 T cells and macrophages. Both attacked and
nonattacked myofibers express high levels of human
leukocyte antigen class I (HLA-I) molecules, a prereq-
uisite for antigen presentation to CD8
 T cells. How-
ever, only a subgroup of HLA-I
 myofibers is attacked
by immune cells. By using IHC, we classified myofi-
bers from five patients with sporadic IBM as attacked
(AIBM) or nonattacked (NIBM) and isolated the intra-
cellular contents of myofibers separately by laser mi-
crodissection. For comparison, we isolated myofibers
from control persons (HCTRL). The samples were an-
alyzed by microarray hybridization and quantitative
PCR. HLA-I up-regulation was observed in AIBM and
NIBM, whereas HCTRL were negative for HLA-I. In con-
trast, the inducible chain of the interferon (IFN)  re-
ceptor (IFNGR2) and several IFN-–induced genes were
up-regulated in AIBM compared with NIBM and HCTRL
fibers. Confocal microscopy confirmed segmental IF-
NGR2 up-regulation on the membranes of AIBM, which
positively correlated with the number of adjacent CD8

T cells. Thus, the differential up-regulation of the IFN-
signaling cascade observed in the attacked fibers is re-
lated to local inflammation, whereas the ubiquitous
HLA-I expression on IBM muscle fibers does not require
IFNGR expression. (Am J Pathol 2011, 179:1347–1359; DOI:
10.1016/j.ajpath.2011.05.055)
Sporadic inclusion body myositis (sIBM) is the most com-
mon inflammatory myopathy in adults 50 years presenting
with progressive weakness and atrophy of both proximal
and distal muscle groups and leading to disability within 5
to 10 years after diagnosis.
1,2 Because sIBM, in contrast to
polymyositis (PM) or dermatomyositis (DM), is notoriously
refractive to immunosuppressive therapies,
3,4 it is assumed
that sIBM is not a primary autoimmune myopathy but that
the inflammatory changes are secondary to as yet unknown
viral or degenerative triggers.
5 Therefore, sIBM is regarded
as the paradigm of a myopathy with distinct degenerative
and inflammatory pathogenetic components.
1,6
The mechanism of inflammatory myofiber injury is unique
in that CD8
 T cells and macrophages focally surround and
invade initially nonnecrotic myofibers.
7 Several articles
6,8,9
provide a review of this information. The myoinvasive CD8

cytotoxic T cells likely recognize (still unknown) antigens
presented by HLA class I (HLA-I) molecules on the myofiber
surface.
10 Antigen-driven recruitment of the myocytotoxic
CD8
 T cells is supported by evidence that the T cells are
clonally expanded, using a restricted repertoire of T-cell
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1347receptors
11–15 and persisting over time in individual pa-
tients.
12,15,16 Moreover, the CD8
 T cells form specific im-
munological synapses with vectorial excretion of perforin
toward the attacked myofibers.
17 This cytotoxicity cannot
be assessed in in vitro co-culturing experiments because
only alloreactive CD8
 T cells were strongly cytotoxic to
allogenic myotubes in co-cultures.
18,19
HLA-I is not detectable on myofibers of healthy sub-
jects.
20 In sIBM, HLA-I is uniformly up-regulated on all
myofibers
21–24; however, CD8
 T cells attack myofibers
in a strictly focal pattern.
25 Obviously, HLA-I expression
is only a necessary, but not sufficient, precondition for a
myofiber to be attacked. There seem to be additional
factors rendering muscle fibers susceptible to inflamma-
tory attack. The aim of the present study was to identify
molecular patterns that are differentially regulated in in-
vaded versus noninvaded muscle fibers, focusing on the
pathways of antigen presentation and processing.
To address the question of why certain myofibers are
attacked, whereas others are spared, we used the unique
properties of the distinct morphological characteristics of
myofibers that remain clearly distinguishable, even under
conditions required for laser microdissection (ie, nonem-
bedded tissue and short incubation times, as described
in Materials and Methods). We separately laser microdis-
sected attacked and nonattacked muscle fibers while
excluding inflammatory cells. We compared attacked
myofibers from IBM muscle (AIBM), nonattacked sIBM
myofibers (NIBM), and healthy control myofibers (HCTRL)
using microarray transcriptome analysis, quantitative
PCR (qPCR), and confocal microscopy. PM or DM could
not serve as controls because PM is heterogeneous
26
and DM lacks CD8
-mediated immunopathological fea-
tures. We found that the attacked muscle fibers in sIBM
differentially overexpressed members of the interferon
(IFN)  signaling cascade. The signature of these molec-
ular changes suggests that they are induced by locally
secreted pro-inflammatory cytokines and, therefore, are a
consequence, rather than the cause, of the focal inflam-
matory attack. In contrast, the ubiquitous up-regulation of
HLA-I on all IBM myofibers seems to be independent of
IFN-–mediated signaling and, therefore, triggered be-
fore inflammation by as yet unknown mechanisms.
Materials and Methods
Patients and Healthy Controls
Muscle biopsy specimens were obtained from five pa-
tients with sIBM (IBM-1 to IBM-5) and three healthy con-
trols (C-1 to C-3) (Table 1). IBM biopsy samples were
obtained at the Neuromuscular Laboratory, Mayo Clinic,
Rochester, MN (A.G.E.). The study was approved by the
local Institutional Review Board (approval no. 1278–03).
Patients’ consent was obtained according to the Decla-
ration of Helsinki.
27 None of the five patients with IBM had
received prior anti-inflammatory treatment. The diagnosis
of definitive IBM was made according to published crite-
ria.
28 Congophilic deposits were visualized in Congo
red–stained sections viewed under rhodamine optics.
Three individuals who had clinically presented with non-
specific myalgia, but had normal serum creatine kinase
values and normal diagnostic biopsy findings (H.L., Univer-
sity of Munich, Munich, Germany), served as controls. C-1
had clinically silent leukocytosis with slight C-reactive pro-
tein elevation at biopsy. All muscle blocks were stored at
80°C. We did not include healthy individuals. For the ex-
periments performed herein, it is absolutely essential that
the samples are shock frozen immediately after surgery
because otherwise the RNA quality will not be sufficient
anymore. RNA, in contrast to DNA or proteins, is degraded
rapidly. Therefore, we were limited to diagnostic biopsy
material. Samples from autopsy cases or from accidents
would not fulfill the listed requirements.
Antibodies
The following antibodies were used in this study.
Mouse anti-human CD8 antibody clone LT8 (Serotec,
Oxford, UK), which we had previously labeled with the
Table 1. Overview of the Basic Characteristics of Patients and Healthy Controls
Patient or control Diagnosis
Age
(years) Sex Biopsied muscle
No. of isolated myofibers to
reach 100,000 m
2*
Patient no.
IBM-1 sIBM 75 Male Biceps brachii 43/37
IBM-2 sIBM 70 Male Vastus lateralis 42/35
IBM-3 sIBM 79 Female Biceps brachii 42/38
IBM-4 sIBM 69 Male Triceps brachii 50/41
IBM-5 sIBM 72 Male Triceps brachii 50/47
Control no.
C-1 Nonspecific myalgia, depression 57 Male Biceps brachii 55
C-2 Nonspecific myalgia 61 Male Biceps brachii 60
C-3 Nonspecific myalgia 52 Male Rectus femoris 57
Five patients with sIBM and three controls were included in the study. Their clinical and histopathological characteristics are listed. The congophilic
deposits were visualized in Congo red–stained sections viewed under rhodamine optics. All biopsy specimens of patients with sIBM showed rimmed
vacuoles, autoaggressive inflammatory exudates, and congophilic inclusions. IBM-2 presented additional mitochondrial dysfunction. IBM-4 and IBM-5
additionally displayed atrophic myofibers. C-1 had a clinically silent leukocytosis with C-reactive protein elevation at biopsy. C-2 showed no abnormalities
on muscle biopsy or laboratory results. C-3 presented with status post statin therapy with transient slight creatine kinase elevation; however, the muscle
histology was negative and there were no other abnormalities. The biopsied muscle is included, along with the number of laser-microdissected myofibers
that, in each case, compose a total of 100,000 m
2 of myofiber area. The number of myofibers varies in the patients with sIBM given the high variability
in myofiber diameter. Control fibers, in general, were smaller on average and, thus, more fibers had to be sampled from controls.
*For patients, data are given as AIBM/NIBM.
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many), was used at 2 g/mL. Mouse anti-human HLA–
avidin-biotin complex (ABC) antibody clone W6/32 (di-
rectly labeled with Alexa 488 by the manufacturer; AbD
Serotec, Düsseldorf, Germany) was used at 0.5 g/mL.
Rabbit anti-human IFNGR2 antibody, polyclonal (order
no. HPA001535; Sigma, Deisenhofen, Germany), was
used at 1.6 g/mL with a goat anti-rabbit Alexa 594–
labeled secondary antibody (order no. A-11037; Invit-
rogen, Darmstadt, Germany) at 4 g/mL. When unla-
beled mouse anti-human CD8 antibody clone LT8
was used (dilution, 10 g/mL; Serotec), a secondary
goat anti-mouse Alexa 488–labeled antibody (order
no. A-11029; Invitrogen) was used at 2 g/mL. For
negative controls, we used isotype-matched IgGs
[mouse IgG1, order no. 555746 (BD Pharmingen,
Heidelberg, Germany); mouse IgG2a, order no.
MCA929XZ (AbD Serotec)] for monoclonal antibodies
and purified IgG (IgG from rabbit serum, order no.
I5006; Sigma) for polyclonal antibodies.
Laser Microdissection
Before the experiments, the RNA quality of each biopsy
was assessed by Agilent Bioanalyzer 2100 following
the recommendations of the manufacturer (Agilent
Technologies, Palo Alto, CA). RNA was heat denatured
at 70°C and diluted to concentrations of 5 to 15 ng/L.
RNA, 1 L, was then used for the Agilent Bioanalyzer
chip (Agilent Technologies, Böblingen, Germany). We
used a staining and laser microdissection protocol
similar to our previously published method.
29 Briefly,
10-m cryostat sections from muscle biopsy speci-
mens of patients 1 to 5 and healthy controls 1 to 3 were
double stained for CD8 and HLA-ABC with the anti-
bodies previously described. To inhibit RNase activity,
all aqueous solutions were pretreated with diethylpy-
rocarbonate and contained 3 U/L Protector RNase
inhibitor (Roche, Mannheim, Germany) and 2% purified
bovine serum albumin (B4287; Sigma). Sections were
mounted on positron emission tomographic films
(P.A.L.M. Microlaser, Bernried, Germany) that had pre-
viously been baked at 180°C for 4 hours, UV irradiated,
and coated with poly-L-lysine. Mounted sections were
stored at 80°C. After drying in a desiccator, rehydrat-
ing in PBS for 10 seconds, and blocking by PBS with
2% bovine serum albumin for 3 minutes, the sections
were co-incubated for 5 minutes with the Cy-3–labeled
anti-CD8 antibody and the Alexa 488–labeled anti-
HLA-ABC antibody. This protocol preserves RNA to a
large extent (see Supplemental Figure S1 at http://
ajp.amjpathol.org). The tissue was then rinsed with
PBS and immediately imaged using a P.A.L.M. Mi-
crobeam-Z microscope (P.A.L.M. Microlaser, Bernried,
Germany). We defined a myofiber as being attacked
when at least three CD8
 T cells were clearly adhering
to the myofiber or at least one CD8
 T cell was invad-
ing the fiber. We focused on fibers that were sur-
rounded and superficially invaded by inflammatory
cells, avoiding fibers that were deeply invaded. A non-
attacked myofiber was defined as such if no CD8
 T
cells could be seen in the proximity (Figure 1, A and B).
Intermediate myofibers not corresponding to either
category were not sampled. The fibers were dissected
from transversally cut biopsy sections. When dis-
secting the myofiber content, we left a safety margin,
avoiding contamination with surrounding and superfi-
cially invading immune cells (Figure 1, C and D). The
specimens were examined within 10 minutes after
staining for attacked and nonattacked myofibers,
which were marked electronically and subsequently
microdissected and laser pressure catapulted into re-
spective reaction tubes (either attacked or nonat-
tacked) containing 20-L TRIzol (Invitrogen), which
were then immediately stored on dry ice. Because of a
strong variability in myofiber diameter typically seen in
sIBM, we chose to sample equal areas rather than
equal numbers of myofibers. The area of each col-
lected myofiber (automatically calculated by the
P.A.L.M. software, P.A.L.M. Microlaser) was recorded,
and a total of 100,000-m
2 myofiber area was col-
lected from each patient with sIBM (attacked and non-
attacked) and each control subject. To minimize con-
tamination with inflammatory cells, we assessed the
dried sections for artifacts by comparing them with
Figure 1. Experimental approach for separate analysis of attacked and
nonattacked myofiber subsets in sIBM. A: The focal nature of inflammatory
infiltrates in IBM. Muscle tissue was stained with anti-CD8 (red) and anti-
HLA-ABC (green) antibodies, as described in Materials and Methods.
A shows a confocal image, C shows unembedded dry tissue. All myofibers
are HLA-ABC positive, but only some are attacked by CD8
 T cells (AIBM),
whereas others are spared (NIBM). B: Myofibers in direct contact with at least
three CD8
 T cells or invaded by at least one CD8
 T cell were defined as
AIBM. Myofibers not in contact with any CD8
 T cells were defined as NIBM.
Ambiguous myofibers were not sampled. Laser-capture microdissection was
used to pressure catapult the different types of myofibers into collecting
tubes. In total, 100,000 m
2 of AIBM and NIBM myofibers was sampled from
each patient with sIBM, as was the same amount of HCTRL myofibers from
each control subject. C: Double immunostaining for HLA-ABC (green) and
CD8 (red), according to the protocol described in Materials and Methods.
Only myofiber tissue (star) was isolated, avoiding surrounding lymphocytes
(red). D: Corresponding bright-light image after the myofiber was dissected
and catapulted out of the tissue. C and D: The numbers in the yellow fields
refer to apparatus parameters. Scale bars  50 m( A and C).
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and embedded with Fluorescent Mounting Medium;
Dako, Glostrup, Denmark). Moreover, we checked for
possible contamination by examining our microarray
data for the expression of lymphocyte-, monocyte-, and
macrophage-specific transcripts (see Supplemental
Table S1 at http://ajp.amjpathol.org).
RNA Isolation and Linear Transcriptome
Amplification
After obtaining 100,000 m
2 of each group of myofibers,
the samples were pooled according to their classifica-
tion. RNA was then extracted using the TRIzol method,
with some modifications as recommended by the linear
amplification protocol. Three rounds of linear T7-based
transcriptome amplification were performed using the Ex-
pressArt-mRNA Amplification Kit, Pico Version (AmpTec,
Hamburg, Germany), according to the instructions of the
supplier, with the following exceptions: for synthesis of
the first cDNA strand, the master mix was prewarmed at
45°C, and 1 L of RNase R was added to each reaction
for the RNA removal step. The resulting yields of ampli-
fied RNA (aRNA) were between 30 and 40 g, derived
from 10 ng of input total RNA.
Microarray Hybridization and Analysis
Amplified cDNA, 15 g, was biotinylated and concomitantly
transcribed into aRNA using the BioArray High Yield RNA
labeling kit (Enzo Life Sciences, Plymouth Meeting, PA).
Biotinylated aRNA was hybridized to HG U133 GeneChip
arrays (Affymetrix, High Wycombe, UK). All chips were nor-
malized using the robust multiarray average or the Gene-
Chip robust multiarray average procedure in R packages
from Bioconductor (Fred Hutchinson Center, Seattle, WA)
(http://www.bioconductor.org, last accessed December
2008). For each probe set, the q values were calculated.
30
The q values mirror the false discovery rate and illustrate the
degree of heterogeneity between different samples (ie,
herein, between different patients). Thus, a low q value
reflects a high significance of a particular expression
change across all samples. To achieve a high concordance
across all patients, we considered only transcripts with a q
value of 20%.
TaqMan Real-Time qPCR
Expression levels of the following genes were measured
in all 13 samples (attacked and nonattacked myofibers
from each of the five patients and C-1 to C-3) by real-time
qPCR using the 5700 Real-Time PCR System (Applied
Biosystems, Foster City, CA): HLA-A, HLA-B, HLA-C,
HLA-E, HLA-F, HLA-G, IFN- receptor  chain (IFNGR1),
IFN- receptor  chain (IFNGR2), STAT1, class II trans-
activator (CIITA), proteasome subunit -type 8 (PSMB8),
HLA-DRA, HLA-DRB, HLA-DPA, HLA-DPB, HLA-DQA, HLA-
DQB,CCL5, and STAT3. aRNA was reverse transcribed into
cDNA using primer D from the ExpressArt-mRNA Amplifi-
cation Kit. Three replicates per sample were assayed for
each gene in a 96-well format plate. For data normalization
across samples, cyclophilin was used as a housekeeping
gene. Normalization of the CT values of each gene and
determination of fold changes in gene expression were
calculated according to the comparative CT method, also
Table 2. Genes Analyzed with TaqMan qPCR
Gene TaqMan qPCR primers/probes
HLA-A Fwd: 5=-CTGAGATGGGAGCTGTCTTC-3=
Rev: 5=-CTATCTGAGCTCTTCCTCCT-3=
P: 5=-FAM-GTAAAGTGTGAGACAGCTGCCTTG-TAMRA-3=
HLA-B Fwd: 5=-CTGAGATGGGAGCCGTCTT-3=
Rev: 5=-CTCCTTTTCCACCTGAACTC-3=
P: 5=-FAM-GAGCTTGAAAAGCCTGAGAGAGC-TAMRA-3=
HLA-C Fwd: 5=-GAGCTGGGAGCCATCTTCC-3=
Rev: 5=-CTGTTGCTGCACGCAGCCT-3=
P: 5=-FAM-CCATCATGGGCATCGTTGCTGG-TAMRA-3=
HLA-E Fwd: 5=-GTCACCCTGAGATGGAAGC-3=
Rev: 5=-CTTGGATCTGTGGTCTCTGG-3=
P: 5=-FAM-CCATCGTGGGCATCATTGCTGG-TAMRA-3=
HLA-F Fwd: 5=-CCTCCAAAGGCACACGTTG-3=
Rev: 5=-GATAGAAACAGAGGGAGCTAC-3=
P: 5=-FAM-CAAGACACACGTGACCCACCAC-TAMRA-3=
HLA-G Fwd: 5=-CCACAGATACCTGGAGAACG-3=
Rev: 5=-GATCATACTGACCTGGCAGC-3=
P: 5=-FAM-CAAGACACACGTGACCCACCAC-TAMRA-3=
IFNGR1 Fwd: 5=-CATCACGTCATACCAGCCATTT-3=
Rev: 5=-CTGGATTGTCTTCGGTATGCAT-3=
P: 5=-FAM-GGTCTGTGAAGAGCCGTTGTCTC-TAMRA-3=
IFNGR2 Fwd: 5=-CCACCAAGCATCCCATTACA-3=
Rev: 5=-CCTTGGACAAGGACAGCTC-3=
P: 5=-GACCCAACTCAGCCCATCTTAGA-3=
STAT1 Fwd: 5=-GAGCAGGTTCACCAGCTTTATG-3=
Rev: 5=-GAAAACGGATGGTGGCAAATG-3=
P: 5=-FAM-CAAGACTGGGAGCACGCTGCCAA-TAMRA-3=
CIITA Fwd: 5=-ACGCCCTGCTGGGTCC-3=
Rev: 5=-AACTCCATGGTGGCACACTG-3=
P: 5=-FAM-ACCTGTCAGAGCCCCAAGGCAGC-TAMRA-3=
PSMB8 Fwd: 5=-GTCCTACATTAGTGCCTTACG-3=
Rev: 5=-GATAGTACAGCCTGCATTCC-3=
P: 5=-FAM-GCTGTGCAGACTGTCAGTAC-TAMRA-3=
HLA-DRA Fwd: 5=-GGCTTGGATGAGCCTCTTC-3=
Rev: 5=-GGACCATCTTCATCATCAAGG-3=
P: 5=-FAM-CAAGCACTGGGAGTTTGATGCTC-TAMRA-3=
HLA-DRB Fwd: 5=-GGAGAGGTTTACACCTGCC-3=
Rev: 5=-GCAAGATGCTGAGTGGAGTC-3=
P: 5=-FAM-GAATGGAGAGCACGGTCTGAATC-TAMRA-3=
HLA-DPA Fwd: 5=-CACAAGTTCCATTACCTGACC-3=
Rev: 5=-GAGCAAGAAAGTTCAACGAGG-3=
P: 5=-CTTCTATGACTGCAGGGTGGAGC-3=
HLA-DPB Fwd: 5=-GGAGTGGAAGGCACAGTCT-3=
Rev: 5=-GAGCAAGAAAGTTCAACGAGG-3=
P: 5=-CGGAGTAAGACATTGACGGGAGC-3=
HLA-DQA Fwd: 5=-CACCAAGGGCCATTGTGAAT-3=
Rev: 5=-CCAGAGAATAGTGCTAGGTC-3=
P: 5=-FAM-CCATCTACAGGAGCAGAAGAATGG-TAMRA-3=
HLA-DQB Fwd: 5=-CCAGAGCAAGATGCTGAGTG-3=
Rev: 5=-GTGCAGAAGCCCTTTCTGAC-3=
P: 5=-FAM-GGCTGGGCCTTATCATCCGTCAA-TAMRA-3=
CCL5 Applied Biosystems assay ID Hs00174575_m1
STAT3 Applied Biosystems assay ID Hs01047580_m1
PPIA Applied Biosystems no. 4333763
GAPDH Applied Biosystems no. 4333764
Classic and nonclassic HLA-I genes were analyzed, as were the major
HLA-II genes DR, DP, and DQ. Moreover, we examined the expression of
genes downstream of IFN-. Forward and reverse primers, and FAM/
TAMRA-labeled probes, are listed. All primer/probe sets were designed
by us, with the exceptions of IFNGR1
33 and CIITA.
34
Fwd, forward; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
P, probe; PPIA, cyclophilin; Rev, reverse.
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CT method.
31,32 For some genes, TaqMan
gene expression assays (Applied Biosystems) were used;
others were analyzed using custom-made primers and
probes (Metabion, Martinsried, Germany). Table 2 lists the
primers and probes used in this study.
Histological Features and Confocal Microscopy
To demonstrate CD8
 T-cell interaction with HLA-I–pos-
itive myofibers, we used 10-m cryosections fixed in
ice-cold acetone. To block nonspecific binding, sections
Table 3. Microarray Data: Transcripts Most Significantly Regulated across All Patients and Controls
Probe set ID Gene title
Raw expression values Fold change
AIBM NIBM HCTRL
q value
(%)
AIBM/
HCTRL
AIBM/
NIBM
NIBM/
HCTRL
205132_at Actin, , cardiac muscle 1 9926.55 5275.13 338.44 0.00 29.33 1.88 15.59
201891_s_at* -2-Microglobulin 12,436.09 11,093.17 1570.33 0.00 7.92 1.12 7.06
216526_x_at* MHC, class I, B; MHC, class I, C;
MHC class I polypeptide-related
sequence A; MHC class I
polypeptide-related sequence B
8959.71 7976.71 705.27 0.00 12.70 1.12 11.31
209140_x_at* MHC, class I, B; MHC, class I, C;
MHC class I polypeptide-related
sequence A; MHC class I
polypeptide-related sequence B
9521.62 7469.66 297.92 0.00 31.96 1.27 25.07
217456_x_at* MHC, class I, E 1503.90 827.43 75.69 0.00 19.87 1.82 10.93
200905_x_at* MHC, class I, E 3383.98 1638.89 57.90 0.00 58.44 2.06 28.30
221875_x_at* MHC, class I, F 1959.54 1293.23 101.36 0.00 19.33 1.52 12.76
211529_x_at* MHC, class I, G 250.88 163.19 12.87 0.00 19.49 1.54 12.68
209040_s_at* Proteasome (prosome, macropain)
subunit,  type, 8 (large
multifunctional peptidase 7)
1751.19 613.20 4.05 0.00 432.37 2.86 151.40
202296_s_at RER1 retention in endoplasmic
reticulum 1 homolog
(Saccharomyces cerevisiae)
16.24 23.27 706.64 0.00 0.02 0.70 0.03
200887_s_at* STAT 1, 91 kDa 7963.49 6296.56 94.89 0.00 83.92 1.26 66.35
AFFX-HUMISGF3A/
M97935_3_at*
STAT 1, 91 kDa 1928.89 1828.85 34.57 0.00 55.80 1.05 52.91
221087_s_at Apolipoprotein L, 3 605.96 373.82 25.70 5.12 23.58 1.62 14.55
208812_x_at* MHC, class I, C 9337.37 6540.77 430.46 5.12 21.69 1.43 15.19
214459_x_at* MHC, class I, C 6556.01 4679.25 371.30 5.12 17.66 1.40 12.60
204806_x_at* MHC, class I, F 753.67 512.69 59.87 5.12 12.59 1.47 8.56
211071_s_at Myeloid/lymphoid or mixed-lineage
leukemia (trithorax homologue,
Drosophila), translocated to 11
4511.40 2944.13 205.20 5.12 21.99 1.53 14.35
202237_at Nicotinamide N-methyltransferase 1944.88 1365.55 21.27 5.12 91.44 1.42 64.20
212845_at Sterile  motif domain containing 4A 22.95 44.53 554.77 5.12 0.04 0.52 0.08
215076_s_at Collagen, type III,  1 (Ehlers-
Danlos syndrome type IV,
autosomal dominant)
6542.53 3846.48 12.69 8.84 515.45 1.70 303.05
213932_x_at* MHC, class I, A 9857.13 7352.34 2127.78 8.84 4.63 1.34 3.46
201137_s_at* MHC, class II, DP  1 1817.92 684.36 37.08 8.84 49.02 2.66 18.46
225061_at DnaJ (Hsp40) homologue, subfamily
A, member 4
1906.51 1525.02 29.68 11.67 64.24 1.25 51.39
211528_x_at* MHC, class I, G 195.97 149.47 16.23 11.67 12.08 1.31 9.21
200814_at* Proteasome (prosome, macropain)
activator subunit 1 (PA28 )
4007.01 3496.38 405.11 11.67 9.89 1.15 8.63
232500_at Chromosome 20 open reading
frame 74
1047.84 210.09 12.61 14.41 83.07 4.99 16.66
217436_x_at* MHC, class I, J (pseudogene) 141.93 114.16 19.59 14.41 7.24 1.24 5.83
226470_at -Glutamyltransferase 7 51.17 51.41 1893.54 16.21 0.03 1.00 0.03
228098_s_at Myosin regulatory light chain
interacting protein
794.08 85.92 27.30 16.21 29.09 9.24 3.15
200743_s_at Tripeptidyl peptidase I 1741.52 1749.31 337.65 16.21 5.16 1.00 5.18
238431_at Transcribed locus 1251.44 347.59 22.14 20.02 56.52 3.60 15.70
215313_x_at* MHC, class I, A 11,623.07 9764.78 968.10 20.02 12.01 1.19 10.09
204070_at Retinoic acid receptor responder
(tazarotene induced) 3
3065.52 1516.95 88.87 20.02 34.49 2.02 17.07
209118_s_at Tubulin,  1a 1608.79 1037.65 48.98 20.02 32.85 1.55 21.19
Raw expression values are provided along with fold expression changes showing regulation of transcripts in AIBM vs HCTRL,A IBM vs NIBM, and NIBM vs
HCTRL. The q value mirrors the false discovery rate. The lower the q value, the higher the significance of the results across all samples (see Materials and
Methods). Herein, we show transcripts that were expressed with a q value of 20%.
*Among these 34 transcripts, 19 can be attributed to components of the classic and nonclassic HLA-I, HLA-II, IFN-–inducible genes and immunopro-
teasome components.
MHC, major histocompatibility complex; RER, retention in endoplasmic reticulum.
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mouse serum in PBS. Then, we stained for CD8 and
HLA-ABC using the antibodies previously described. To
confirm IFNGR2 expression on the protein level, we fixed
the tissue in 4% paraformaldehyde at room temperature
and washed with PBS, then blocked unspecific binding
with 2% bovine serum albumin–2% goat serum in PBS,
and subsequently stained for CD8 (same as previously
described, unlabeled) and rabbit anti-human IFNGR2 an-
tibody (Sigma). After washing in PBS, sections were in-
cubated with goat anti-mouse Alexa 488–labeled anti-
body and goat anti-rabbit Alexa 594–labeled antibody
(both from Invitrogen). For negative controls, we used
isotype-matched IgGs (mouse IgG1 for anti-CD8 and
mouse IgG2a for anti-HLA-ABC) for monoclonal antibod-
ies and purified IgG (rabbit IgG) for polyclonal antibod-
ies. The staining was visualized using a Zeiss Axiovert
200M inverted microscope (Zeiss, Göttingen, Germany).
For confocal microscopy, a Leica TCS SP2 system was
used (Leica Microsystems, Wetzlar, Germany). For image
analysis, we used the ImageJ software written by Wayne
Rasband at the US NIH, version 1.42m (http://rsbweb.
nih.gov/ij/index.html, last accessed September 2010).
Quantitative Analysis of IFNGR2 Signal Distribution
Cryosections were stained for IFNGR2 and CD8 and im-
aged as previously described. Myofibers were photograph-
ically documented and classified into four groups accord-
ing to their extent of membrane circumference positivity for
IFNGR2: group 1, 80%; group 2, 50% to 80%; group 3,
20% to 50%; and group 4, 20%. For each myofiber, we
counted the number of adjacent CD8
 T cells and calcu-
lated the medians. Two investigators (J.I. and Ingrid Ei-
glmeier) independently performed this analysis for each
patient. A Mann-Whitney U-test was performed to determine
whether the medians of adjacent CD8
 T cells of group 1
(80% IFNGR2 positivity) and group 4 (20% IFNGR2
positivity) differed significantly. The two-tailed P value was
calculated, as was the Mann-Whitney U-test value. This
analysis was performed for four of five patients with sIBM
because of lack of biopsy material from patient 4.
Results
Hints from Microarray Analysis of Attacked and
Nonattacked Myofibers
We isolated AIBM,N IBM, and HCTRL myofibers from five
patients and three control individuals, as described in
Materials and Methods and illustrated in Figure 1. At least
100,000 m
2 of total myofiber area was isolated from
each fiber subset of each patient and from each control.
We amplified RNA from these laser-microdissected sam-
ples and hybridized the aRNA to HG U133 GeneChip
microarrays. The microarray data were cross-checked for
inadvertent sampling of inflammatory cells (see Supple-
mental Table S1 at http://ajp.amjpathol.org). We focused
on transcripts that were regulated with q values of 20%
(Table 3) to ensure that interpatient variation is mini-
mized. Of the 34 transcripts with a q value of 20%, 19
belonged to HLA-I, HLA-II, or inflammatory signaling
genes. Next, we explored whether these molecules are
differentially expressed in AIBM versus NIBM versus HCTRL
myofibers. Of these 34 transcripts, six were polymorphic
HLA-I (ie, HLA-A, HLA-B, or HLA-C). Both AIBM and NIBM
myofibers showed a strong up-regulation of HLA-ABC
expression compared with HCTRL myofibers (average fold
change for AIBM/HCTRL  16.78, NIBM/HCTRL  12.95, and
AIBM/NIBM  1.29). Moreover, seven nonpolymorphic HLA-I
Figure 2. Comparison of transcript levels in attacked, nonattacked, and
healthy control myofibers using TaqMan qPCR. Relative expression values
were calculated using the 2
CT method with cyclophilin as the endogenous
control. Each symbol represents the mean of triplicate experiments per-
formed on one sample. Five AIBM samples (circles), five NIBM samples
(squares), and three HCTRL samples (triangles) were included in the study.
Colors correspond to individual patients (IBM-1, pink; IBM-2, green; IBM-3,
gray; IBM-4, blue; IBM-5, yellow) and controls (C-1, white; C-2, gray; C-3,
black), and medians are shown for each subset. Dashed line, detection limit.
The following are shown: HLA-A (A), HLA-B (B), HLA-C (C), HLA-E (D),
HLA-F (E), HLA-G (F), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (G). Data for HLA-E and HLA-G from AIBM of patient 4 were out of
range (100) and are omitted. HLA-A and HLA-B were strongly up-regulated
in both attacked and nonattacked sIBM myofibers. The nonclassic HLA (ie,
HLA-E, HLA-F, and HLA-G) displayed a pattern similar to that of HLA-A and
HLA-B. GAPDH was used as an additional endogenous control. As expected,
its expression pattern largely mirrors that of cyclophilin in that it is un-
changed in all samples.
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with low q values (average fold change for AIBM/HCTRL 
23.63, NIBM/HCTRL  13.74, and AIBM/NIBM  1.62).
Two probe sets of STAT1, a mediator of IFN signaling,
were regulated, with a q value of 0%, thus being highly
significant across all patients. STAT1 was strongly ex-
pressed in AIBM and NIBM and undetectable in HCTRL.
HLA-DPB1 was the only HLA-II transcript with a q value
20%. In contrast to HLA-I, HLA-DPB1 was up-regulated
2.66-fold in AIBM versus NIBM myofibers. PSMB8, a major
constituent of the immunoproteasome, had a q value of
0% as well and was differentially regulated in AIBM versus
NIBM (fold change  2.86).
Several transcripts important for inflammatory sig-
naling and antigen presentation were overexpressed in
global microarrays from sIBM biopsy specimens by
other researchers (see Supplemental Table S2 at
http://ajp.amjpathol.org). Although only some of the
transcripts had significantly low q values, our results
allow us to attribute these regulation patterns to spe-
cific myofiber subsets. On the other hand, Ig genes
were absent in our myofiber-specific microarray stud-
ies (see Supplemental Table S1 at http://ajp.amjpathol.
org). This ensures that cells of the B lineage, and not
myofibers, are the source of Igs in sIBM tissue.
35,36
TaqMan qPCR Confirms Global HLA-I
Up-Regulation in sIBM Muscle Fibers
We analyzed aRNA from laser-microdissected AIBM,
NIBM, and HCTRL myofibers using TaqMan qPCR. Relative
expression values were calculated for all TaqMan results
using the 2
CT method.
31,32
We found that all members of the HLA-I family were
up-regulated in both AIBM and NIBM compared with HCTRL
myofibers (Figure 2). This agrees with our microarray data
and with previous immunohistological studies
21 and sup-
ports the overall validity of our experimental approach.
Differential Regulation of IFN- Downstream
Signaling Pathways
We found several IFN-–inducible molecules to be differ-
entially up-regulated in AIBM versus NIBM and HCTRL myo-
fibers. To see whether myofibers are susceptible to
IFN-, we analyzed the expression of both chains of
IFNGR and its major downstream mediator STAT1 in AIBM
versus NIBM and HCTRL myofibers with TaqMan qPCR.
Both IFNGR1 and IFNGR2 were overexpressed in AIBM.
In NIBM and HCTRL myofibers, the expression of both
IFNGR chains ranged below the detection limit in most
cases (Figure 3, A and B). STAT1 was up-regulated in
AIBM and below the detection limit in NIBM and HCTRL
(Figure 3C). Two other major downstream effector pro-
teins of IFN-, the immunoproteasome component
PSMB8
37 and CIITA,
38 were up-regulated in AIBM com-
pared with NIBM and HCTRL (Figure 3, D and E). In one
patient, the levels of all three downstream transcripts (ie,
STAT1, PSMB8, and CIITA) were particularly high com-
pared with the other patients. This reflects a certain in-
terindividual variability that is to be expected in such a
cohort.
Figure 3. Comparison of transcript levels in attacked, nonattacked, and healthy control myofibers using TaqMan qPCR. Relative expression values were calculated
using the 2
CT method with cyclophilin as the endogenous control. The following are shown: IFNGR1 (A), IFNGR2 (B), STAT1 (C), PSMB8 (D), CIITA (E),
HLA-DRA (F), HLA-DRB (G), HLA-DPA (H), HLA-DPB (I), HLA-DQA (J), HLA-DQB (K), CCL5 (L), and STAT3 (M). The legend to Figure 2 provides a detailed
explanation of all symbols. IFNGR1, IFNGR2, STAT1, CIITA, and PSMB8, as well as HLA-DRA and HLA-DRB, were overexpressed in attacked myofibers compared
with nonattacked myofibers and healthy controls. For HLA-DP, the difference between attacked and nonattacked myofibers was less pronounced. HLA-DQ was
only detectable in two of five patients with sIBM.
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regulation results in effective HLA-II overexpression in
AIBM. We looked at the expression of the respective 
and  chains of HLA-DR, HLA-DP, and HLA-DQ. HLA-
DRA and HLA-DRB were up-regulated in AIBM com-
pared with NIBM and HCTRL myofibers (Figure 3, F and G). In
the case of HLA-DPA and HLA-DPB, the difference in
overexpression between AIBM and NIBM was less striking
(Figure 3, H and I). HLA-DQA and HLA-DQB showed the
same tendency, albeit with lower expression levels (Figure
3, J and K).
Because tumor necrosis factor (TNF)- induces
chemokine ligand (CCL) 5 [regulated on activation nor-
mal T-cell expressed and secreted (RANTES)] via STAT3
in vascular smooth muscle cells and many other nonlym-
phoid cell types,
39 we investigated the transcriptional
activity of the CCL5-STAT3 system in our laser-microdis-
sected myofiber subsets from patients with sIBM. Al-
though RANTES and STAT3 levels were generally low,
and the expression patterns were heterogeneous across
all patients and controls, median values indicate a ten-
dency for higher CCL5 expression in attacked myofibers
compared with nonattacked myofibers and healthy con-
trols (Figure 3, L and M).
Confocal Microscopy Confirms Differential
IFNGR2 Expression in AIBM versus NIBM
Myofibers
On binding of IFN-, IFNGR1 is internalized in a complex
with STAT1, whereas IFNGR2, also known as the induc-
ible chain of the IFN- receptor, remains on the cell
surface.
40 To evaluate IFNGR2 expression on the protein
level, we double stained cryosections from five patients
with sIBM and three controls for IFNGR2 and CD8. We
found that a proportion of myofibers of patients with sIBM
stained positive for IFNGR2. The IFNGR2 was not uni-
formly distributed in patients with sIBM. Some myofibers
were positive for IFNGR2 along their entire surface. Other
myofibers showed only partial segmental membrane
staining, and yet others were entirely negative. This vari-
ability of IFNGR2 membrane staining was similar in all five
patients with sIBM who were included in our study. By
Figure 4. IFNGR2 expression on the protein level in patients with sIBM and healthy controls. IFNGR2 (Alexa 594 in red) and CD8 (Alexa 488 in green) were
stained as described in Materials and Methods and visualized with confocal microscopy. Technical controls were performed with rat IgG (rIgG) for anti-IFNGR2
antibody and mouse Ig isotype 1 (mIgG1) for anti-CD8 antibody under identical experimental conditions. Left to right: Images are organized as follows: green
channel (CD8 or respective control), red channel (IFNGR2 or respective control), and overlay.
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positive for IFNGR2 (Figure 4).
We then asked whether the extent of IFNGR2 expres-
sion might be related to the extent of inflammatory
changes around individual fibers. To this end, we classi-
fied myofibers into four groups according to the extent of
IFNGR2 surface expression as follows: group 1, 80%;
group 2, 50% to 80%; group 3, 20% to 50%; and group 4,
20% surface staining (Figure 5). Control sections
stained in the same experiment were uniformly negative
for IFNGR2 (Figure 4). Two independent observers (J.I.
and Ingrid Eiglmeier) evaluated the numbers of attacking
CD8
 T cells that were in direct contact with each myo-
fiber for each classified myofiber (Figure 6). A Mann-
Whitney U-test was performed to determine whether the
distributions of adjacent CD8
 T-cell numbers per myo-
fiber in groups 1 and 4 differed significantly in all ana-
lyzed patients (Figure 6). In patient IBM-1, the median
CD8
 T-cell numbers were 5 and 1 (observer Ingrid
Eiglmeier: Mann-Whitney U-test  9.5, P  0.0001) and 6
and 1 (observer J.I.: Mann-Whitney U-test  5.5, P 
0.0001), respectively. In patient IBM-2, the median CD8

T-cell numbers were 4 and 0 (observer I.E.: Mann-Whit-
ney U-test  0, P  0.0278) and 5 and 0.5 (observer J.I.:
Mann-Whitney U-test  0, P  0.0223), respectively. In
patient IBM-3, the median CD8
 T-cell numbers were 5
and 1 (observer Ingrid Eiglmeier: Mann-Whitney U-test  3,
P  0.0072) and 5.5 and 1 (observer J.I.: Mann-Whitney
U-test 0.5, P0.0011), respectively. In patient IBM-5, the
median CD8
 T-cell numbers were 6 and 0 (observer IE:
Mann-Whitney U-test  13, P  0.0001) and 7 and 0 (ob-
server J.I.: Mann-Whitney U-test  10.5, P  0.0001), re-
spectively. (All P values were two tailed.) The results reveal
a positive correlation between the density of the focal in-
flammatory infiltrate and the extent of IFNGR2 surface ex-
pression, indicating that IFNGR2 is up-regulated on myofi-
bers by locally produced pro-inflammatory cytokines.
Discussion
In sIBM, essentially all muscle fibers express HLA-I.
6 By
contrast, the attacking CD8
 T cells follow a strictly focal
pattern. In the present study, we sought to identify differ-
ences between the following: AIBM,N IBM, and HCTRL.W e
focused on the molecular pathways of antigen presenta-
tion. We did not investigate PM or DM because PM is
heterogeneous
26 and DM lacks CD8
-mediated muscle
fiber injury. We found high levels of HLA-I in both AIBM
and NIBM myofibers. In contrast, the receptor for IFN-
was overexpressed in AIBM compared with NIBM myofi-
bers, indicating increased susceptibility of AIBM to IFN-
downstream signaling.
Ubiquitous Up-Regulation of HLA-I
Most tissues constitutively express HLA-I molecules.
Muscle is an exception in that HLA-I is normally unde-
tectable but up-regulated in inflammatory myopa-
thies.
21,24,41 In sIBM, HLA-I expression is essentially
ubiquitous on all myofibers. Consistent with this well-
Figure 5. IHC demonstrates differential IFNGR2 expression in patients with
sIBM. IFNGR2 (Alexa 594 in red) and CD8 (Alexa 488 in green) were stained
as described in Materials and Methods and visualized with confocal micros-
copy. Although some myofibers were strongly positive for IFNGR2 along
their entire surface, others were only segmentally positive or negative. The
strongly positive myofibers were often heavily attacked by CD8
 T cells.
Herein, representative examples from one patient are shown. Four groups
were defined according to IFNGR2 membrane positivity: group 1, 80% of
the myofiber membrane positive for INFGR2; group 2, 50% to 80% of the
myofiber membrane positive for INFGR2; group 3, 20% to 50% of the myo-
fiber membrane positive for INFGR2; and group 4, 20% of the myofiber
membrane positive for INFGR2. Images are organized clockwise from top
left as follows: transmission, green channel (CD8 or respective control), red
channel (IFNGR2 or respective control), and overlay. Scale bar  50 m.
Figure 6. Relationship between extent of membrane positivity for IFNGR2
and number of adjacent CD8
 T cells. Each dot represents an individual
myofiber. Each myofiber was assigned to a group according to the criteria
discussed in Results and in Figure 5, and the number of adjacent CD8
 T cells
was counted. In the previously described graphs, the number of adjacent
CD8
 T cells was plotted against the respective group for each myofiber.
Results from two independent observers (green and pink) are shown side by
side. Mann-Whitney U-tests were performed to determine statistical signifi-
cance (*P  0.01, **P  0.001, and ***P  0.0001). Patient IBM-4 was not
included because of lack of material for a systematic analysis.
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tion of classic and nonclassic HLA-I transcripts in both
AIBM and NIBM (Figure 7). This confirms and extends
previous observations that nonclassic HLA-G is up-reg-
ulated on muscle fibers in inflammatory myopathies.
42
Because up-regulation of HLA-I on sIBM myofibers is
independent of the presence of local inflammatory cells,
6
and because it may occur in the absence of an IFN-
signature (as shown by our present results from NIBM), it
appears that HLA-I is induced by unknown triggers up-
stream of the IFN-–related changes. Other inflammatory
mediators (eg, TNF-) may precede and subsequently
potentiate the IFN- cascade, as suggested by our find-
ings on the up-regulation of CCL5-STAT3 in attacked
myofibers, which is a TNF-–inducible chemokine sys-
tem.
39 IFN- is a further important inflammatory mediator
implicated in the pathogenesis of inflammatory myopa-
thies. In juvenile DM, IFN- up-regulated HLA-I and sev-
eral IFN-–inducible genes, possibly through up-regula-
tion of IL1-/.
43,44 The interplay between IFN- and
IFN- demonstrated in juvenile DM may play a role in
sIBM as well.
The nonhistone nuclear protein alarmin high-mobility
group box 1 protein may be a further important upstream
inducer of HLA-I in sIBM. High-mobility group box 1 pro-
tein up-regulation has been demonstrated in myofibers of
patients with inflammatory myopathies early in the dis-
ease course. Moreover, high-mobility group box 1 protein
up-regulated HLA-I on muscle cells in vitro.
45
Another possible explanation for IFN-–independent
HLA-I induction may be a viral infection, given the known
association of inflammatory myopathies with human T-
lymphotropic virus I and HIV.
46–48 Moreover, viral infec-
tion induced HLA-I on cultured human myoblasts inde-
pendently of IFN-.
49 Although there is no current
evidence that HLA-I can be induced by degenerative
factors, the HLA-I up-regulation in sIBM might be related
to the observed degenerative changes.
50–52 Amyloid-
precursor protein and embryonic myosin variants
showed reasonable q values between 20% and 40%
(data not shown). These findings, which need to be ex-
tended and confirmed in future studies, would be con-
sistent with the concept that inflammatory and degener-
ative changes in sIBM are mutually related.
53,54 An
additional aspect not addressed in our study is the ex-
pression of B-crystallin in so-called X fibers.
55 Previous
observations that X fibers are otherwise morphologically
normal, and are not (yet?) attacked by inflammatory cells,
suggested that B-crystallin expression is induced in
these fibers by an unknown proximal triggering event,
perhaps infection with an unknown virus. It will be inter-
esting to apply our microdissection approach to the in-
vestigation of X fibers in future studies.
The precise pathogenetic role of HLA-I overexpression
remains uncertain. In animal models, overexpression of
major histocompatibility complex I was associated with
inflammatory and degenerative myopathic changes, pos-
sibly related to an endoplasmic reticulum stress re-
sponse.
56–58 Furthermore, HLA-I expression is defini-
tively a prerequisite for CD8
 T-cell–mediated muscle
fiber injury because CD8
 T cells recognize HLA-I–
bound antigenic peptides. Previous studies
59 have dem-
onstrated HLA-I up-regulation in human myoblasts incu-
bated by IFN-. The difference might be explained by the
fact that mature myofibers differ from less differentiated
myotubes and myoblasts. However, as supported by our
findings, HLA-I is only a necessary, but by no means
sufficient, precondition for a CD8
 T-cell–mediated at-
tack, and HLA-I expression alone cannot explain the fo-
cal character of inflammation in sIBM.
Up-Regulation of IFN- Receptor in Attacked
Myofibers
The crucial upstream protein required for initiation of
downstream IFN- signaling is the IFN- receptor, which
was expressed by AIBM but not NIBM or HCTRL myofibers
by qPCR (Figure 7). When IFN- binds to the IFN- re-
ceptor, the complex of IFN-, IFNGR1, and STAT1 trans-
locates into the nucleus while IFNGR2 remains on the cell
surface.
40,60 In sIBM muscle, IFNGR2 protein expression,
Figure 7. Scheme for changes in the molecular
pattern of inflammatory signaling, antigen pro-
cessing, and presentation in attacked myofibers.
HLA-I molecules are up-regulated in all IBM
myofibers. We show the pronounced effect of
IFN-–induced CIITA on HLA-II by a continuous
arrow and the relatively small effect of CIITA on
HLA-I expression (Gobin et al, 1998) as a dotted
arrow. However, the effect of CIITA cannot be
held responsible for the initial IFN-–indepen-
dent and probably ubiquitous HLA-I up-regula-
tion. In AIBM, we found up-regulation of IFN-
pathway components IFNGR1 and IFNGR2. The
response to IFN- explains the up-regulation of
IFN-–inducible genes, such as STAT1, CIITA,
PSMB8, and HLA-II,i nA IBM.
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heterogeneous and related to the presence of inflamma-
tory cells. Quantitative analysis of the relationship be-
tween inflammatory cells and segmental IFNGR2 expres-
sion revealed a positive correlation between the extent of
IFNGR2 surface expression on myofibers and the num-
ber of adjacent CD8
 T cells in all patients, confirming
our qPCR findings.
Up-Regulation of IFN-–Induced Transcripts
An important downstream component of the IFN- sig-
naling cascade is STAT1 (Figure 7). A role for STAT1
overexpression has been demonstrated for DM and
PM.
61 Our qPCR results revealed that STAT1 is differen-
tially overexpressed in AIBM myofibers, which is consis-
tent with our observation that IFNGR2 is preferentially
expressed in AIBM myofibers.
CIITA (Figure 7) is the most important transcription
factor for the induction of HLA-II.
62 To some extent, CIITA
can induce HLA-I as well.
63 CIITA is strongly regulated
by IFN-, which can induce CIITA in nonlymphoid cells.
38
We show, for the first time to our knowledge, an up-
regulation of CIITA in CD8
 T-cell–attacked myofibers of
patients with sIBM. Literature on the expression of HLA-II
in sIBM is controversial. Global tissue profiling has dem-
onstrated an increase of HLA-DP, HLA-DQ, and HLA-DR
in sIBM; however, the cellular source remained uncer-
tain.
35 Immunohistochemical studies addressing the ex-
pression of HLA-II on myofibers in inflammatory myopa-
thies are sparse. One study
64 analyzed the expression of
HLA-II in DM and PM and provided evidence that the
HLA-DR expression is independent of inflammatory infil-
trates. However, in sIBM, we found differential HLA-DR
overexpression in CD8
 T-cell–attacked myofibers (Fig-
ure 7). This discrepancy might be related to differences
between the different myopathies, with IBM being domi-
nated by CD8
 T cells and DM by CD4
 T cells; PM is a
heterogeneous disease. The pathogenic relevance of
IFN-–induced HLA-II expression is unknown, probably
initiated by TNF-.
65 However, (auto-) antigen presenta-
tion to CD4
 T cells is unlikely because the endomysial
inflammatory infiltrate in sIBM consists mainly of CD8
 T
cells.
7
The IFN-–inducible catalytic immunoproteasome sub-
unit PSMB8 (LMP-2) generates peptides with an in-
creased affinity for HLA-I.
35 Previous global microarray
profiling studies
35,36 showed a strong overexpression of
PSMB8 in inflammatory myopathies, without revealing the
cellular source. Our microarray and qPCR data attribute
up-regulation of PSMB8 to AIBM myofibers. This indicates
an up-regulated IFN- signature in AIBM, consistent with
our other findings.
It seems likely that additional IFN-–inducible tran-
scripts are up-regulated in AIBM myofibers. qPCR
showed up-regulation of the CCL5-STAT3 system in
AIBM myofibers (Figure 3, L and M). CCL5, also known
as RANTES, is synergistically up-regulated by TNF-
and IFN-
66,67 and would be expected to attract acti-
vated T cells,
39,68 thereby contributing to the local
pro-inflammatory loop. Previous work
69 has shown that
TNF- up-regulates the TSP1-CD36-CD47 complex in
cultured myoblasts and that the TSP1-CD36-CD47 was
up-regulated in sIBM. The multifold synergies between
TNF- and IFN- likely play an important role in sIBM
pathophysiological features. As demonstrated herein,
multiple transcripts that are known to be synergistically
up-regulated by TNF- and IFN-, such as the CCL5-
STAT3 system and IFNGR1/2, are induced on attacked
myofibers. Indeed, previous studies
70,71 have suggested
that the myofibers themselves are capable of producing
IFN-–inducible chemokines that could potentially direct
activated T cells. Clearly, the role of chemokines needs to
be further explored in future studies.
Comparison with Other Microarray Studies in
Human Inflammatory Myopathies
Previous microarray studies
35,36 in IBM, PM, DM, and
degenerative muscle diseases were global and did not
distinguish between muscle-derived transcripts and
genes overexpressed by leukocytes present in the bi-
opsy specimen. Determining the source of transcripts
overexpressed in inflammatory myopathies is all the
more important given that the ability of muscle fibers to
produce certain chemokines and other proteins under
inflammatory conditions has repeatedly been demon-
strated.
70–72
Regarding IBM, previously reported global microar-
ray studies have demonstrated a strong up-regulation
of HLA-I, HLA-II, PSMB8, several IFN-induced genes,
and certain cytokines, such as RANTES (CCL5) and
monocyte induced gamma-interferon (MIG, CXCL9)
(see Supplemental Table S2 at http://ajp.amjpathol.
org). By comparison, our study allows changes of ex-
pression patterns, in particular the overexpression of
IFN-–inducible transcripts, to be attributed, for the
first time to our knowledge, to particular subgroups of
fibers. On the other hand, our data attribute the previ-
ously described Ig overexpression to tissue-invading
B cells (see Supplemental Table S1 at http://ajp.
amjpathol.org).
36,73
Conclusion and Model
In conclusion, we found that the receptor for IFN- is
selectively up-regulated in attacked IBM myofibers (Fig-
ure 7). This raises the crucial question of what comes
first: focal inflammation or focal induction of antigen pre-
sentation and processing pathways in the attacked mus-
cle fiber? Although we have not yet identified the initial
trigger that leads to the up-regulation of HLA-I expres-
sion, we may delineate the sequence of later events.
Our findings suggest a scenario that helps explain the
focal nature of the inflammatory attack in IBM muscle.
First, ubiquitous HLA-I expression is induced on essen-
tially all myofibers by unknown, possibly infectious or
inflammatory, proximal triggers, thereby providing a nec-
essary precondition for antigen recognition by CD8
 T
cells. Second, a CD8
 T cell recognizes a surface-ex-
posed HLA-I–bound antigen on a myofiber. This initial
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ever, once such a contact is established, a specific im-
munological synapse is formed, with vectorial orientation
of perforin toward the area of contact.
17 On antigen rec-
ognition and activation, the T cell starts to secrete pro-
inflammatory cytokines and chemokines, thereby attract-
ing and activating additional inflammatory cells, including
macrophages, dendritic cells, and B cells. The cytokines
produced by the inflammatory cells induce IFN- re-
ceptor expression on the attacked and perhaps adja-
cent muscle fibers, which thereby become susceptible
to IFN-–mediated stimulation. IFN-–mediated signal-
ing induces a cascade of secondary changes in the
attacked fibers, increasing their susceptibility to in-
flammatory attack. In this way, an initial antigen recog-
nition event by a CD8
 T cell on an HLA-I–positive
myofiber would be amplified, leading to strong focal
inflammatory changes.
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